Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · Arvaya Healthcare Limited · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Arvaya Healthcare Limited
BSE: 524723

Arvaya Healthcare Limited

StateQ1 FY27 filed
Last close · 20 Sept 2026121.70
Market cap0.6k cr
TTM P/E · P/B · EV/EBITDA · 9.27 ·

Rebranded from Bijoy Hans Limited to Arvaya Healthcare Limited effective 13 July 2026 on BSE, and is pivoting into healthcare through the proposed 100% acquisition of Sushodha Institute of Gastroenterology (SIGPL), a super-specialty gastroenterology hospital in Shivamogga. The deal is valued at about Rs 15.49 crore via a share swap of 38.71 lakh equity shares at Rs 40 each, pending shareholder approval via postal ballot. The acquirer's standalone FY26 revenue is Rs 9.11 crore, with total assets of Rs 140.62 crore and an EBITDA margin of 23.3%. Costs are dominated by other operating expenses at 57.3% of revenue, followed by employee costs at 20.8%, depreciation at 6.8% and materials at 6.8%. The board has also approved a Rights Issue of up to Rs 210 crore and is shifting the registered office from Assam to Maharashtra, while appointing a new Executive Director previously at SeCURE Hospitals, Cloudnine, Vaatsalya, and Vikram Hospitals. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Gastroenterology hospital services. Small, transition-stage healthcare services company; single-asset acquisition pending

What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.

Exhibit 1: Financial summary, FY26FY26 (all audited; no estimate years)

₹ crore · consolidatedFY26
Revenue9
EBITDA (ex other income)1
margin %7.9
Owners' profit1
EPS, as reported (₹)0.69
ROE % · ROCE %1.4 · 1.4
Debt / equity (x)0.17
Cash from operations(3)
Capex(5)
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Arvaya Healthcare Limited · 22 September 2026Page 2 of 3

Exhibit 2: Quarterly performance, last 2 quarters

₹ croreQ4 FY26Q1 FY27
Revenue930
Profit before tax21
Net profit11
EPS (₹)1.250.08
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Arvaya Healthcare Limited · 22 September 2026Page 3 of 3

Exhibit 3: Filings of the last 90 days, with the measured price reaction

Date · filingCategoryImportance1-day %5-day %
21 Sept 2026 · Arvaya Healthcare 41st AGM: Subsidiary, Acquisition and Rights Issue Announcedboard shareholder meetingsmedium
19 Sept 2026 · Arvaya Healthcare sets up insurance broking subsidiarystrategic transactionsmedium
29 Aug 2026 · Newspaper publication of 41st AGM notice by Arvaya Healthcarecomplianceminimal
28 Aug 2026 · AGM web link notice for 21 Sept 2026 meetingboard shareholder meetingslow
28 Aug 2026 · 41st Annual Report for FY 2025-26 and AGM Notice filedboard shareholder meetingsmedium
28 Aug 2026 · Arvaya Healthcare 41st AGM Sep 21, 2026; RPTs and IP acquisition on agendaboard shareholder meetingslow
27 Aug 2026 · Arvaya Healthcare: 41st AGM notice published in newspaperscomplianceminimal
26 Aug 2026 · Board Approves IP Portfolio Buy from Related Party for Up to 10 Croreregulatory legalmedium
21 Aug 2026 · Board to consider acquisition from related party on Aug 26strategic transactionshigh
21 Aug 2026 · Registered office shift from Assam to Maharashtracomplianceminimal
Source: exchange announcements; reaction = close-to-close from the filing's session.

How to read this document

Where a broker report showsThis document showsWhy
A rating (BUY / ADD / REDUCE / SELL)A state: the latest filed quarter and the measured reactionsan event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upsideThe current price and the multiples against the groupa target is a forecast; a multiple is a measurement
Estimate years marked EMore audited years; no estimatesMarketPing publishes no forecasts — your own model lives on the Models page

Sources, method and disclosures

This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.

Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in